We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Understand the common and serious side effects of Ebglyss (Lebrikizumab) for atopic dermatitis. Learn about injection site reactions, eye issues, infections, and when to seek medical help for safe treatment.

Sleeping tablets can help manage insomnia and sleep disorders when used correctly. This guide explains types, benefits, risks, and safe usage tips for better sleep health.
April 11, 2026
Explore the short-term and long-term effects of Adderall on the brain, including its uses, side effects, risks of misuse, and the importance of medical supervision for safe and effective treatment.
April 1, 2026

Ebglyss, known by its generic name Lebrikizumab, is a relatively new biologic medication approved for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older who are candidates for systemic therapy. As a targeted therapy, Ebglyss works by blocking the action of interleukin-13 (IL-13), a key cytokine involved in the inflammation and skin barrier dysfunction characteristic of atopic dermatitis. While offering significant relief for many patients, like all medications, Ebglyss comes with a profile of potential side effects. Understanding these effects is crucial for patients, caregivers, and healthcare providers to make informed decisions and manage treatment effectively. This comprehensive guide will delve into the common, serious, and rare side effects associated with Ebglyss, providing essential information on symptoms, management, and when to seek medical attention.
Lebrikizumab (Ebglyss) is a human monoclonal antibody that specifically targets and inhibits interleukin-13 (IL-13). IL-13 plays a central role in the pathogenesis of atopic dermatitis by promoting inflammation, itching, and skin barrier defects. By neutralizing IL-13, Ebglyss aims to reduce inflammation, improve skin lesions, and alleviate the intense itch associated with the condition. It is administered via subcutaneous injection, typically every two or four weeks, depending on the treatment phase and individual response.
Most individuals taking Ebglyss experience mild to moderate side effects that are often manageable and tend to diminish over time as the body adjusts to the medication. It's important to discuss any persistent or bothersome side effects with your doctor.
As Ebglyss is administered by injection, reactions at the injection site are among the most common side effects. These reactions are usually mild and temporary.
Eye-related side effects, particularly conjunctivitis (pink eye), have been reported in patients taking Ebglyss.
URTIs, such as the common cold, are also frequently observed in patients using Ebglyss.
Headaches are another common side effect reported by individuals on Ebglyss.
There is an increased risk of herpes virus infections, including oral herpes (cold sores) and herpes zoster (shingles), in patients treated with Ebglyss.
While less common, some side effects can be serious and require immediate medical attention. It's crucial to be aware of these potential risks.
Severe allergic reactions, though rare, are possible with Ebglyss.
Beyond conjunctivitis, more serious eye conditions like keratitis (inflammation of the cornea) or even corneal ulcers can occur.
Ebglyss may increase the risk of certain parasitic infections. Patients with pre-existing parasitic infections should be treated before starting Ebglyss.
Some patients have reported new onset or worsening joint pain while on Ebglyss.
It is important to maintain open communication with your healthcare provider while on Ebglyss. You should contact your doctor if:
Effective management of Ebglyss side effects often involves a combination of strategies:
The side effects of Ebglyss are primarily related to its mechanism of action, which involves modulating the immune system by inhibiting IL-13. While this action is beneficial for treating atopic dermatitis, it can also lead to unintended consequences:
Diagnosing and monitoring side effects typically involves a multi-pronged approach:
Treatment for Ebglyss side effects depends on the specific effect and its severity:
While not all side effects can be entirely prevented, certain measures can help minimize risks and ensure safe treatment:
The safety of Ebglyss during pregnancy and breastfeeding has not been extensively studied in humans. Animal studies have not shown direct harmful effects, but caution is generally advised. If you are pregnant, planning to become pregnant, or breastfeeding, discuss the potential risks and benefits with your doctor.
Ebglyss is approved for adolescents aged 12 years and older. The safety and efficacy in children younger than 12 have not been established.
No overall differences in safety or effectiveness were observed between elderly patients (65 years and older) and younger adult patients, but caution is always advised due to the higher likelihood of co-existing conditions and polypharmacy in older adults.
Patients with chronic infections or a history of recurrent infections should discuss these with their doctor, as Ebglyss may increase the risk of certain infections.
Currently, there are no specific studies on drug-drug interactions with Ebglyss. However, as it modulates the immune system, caution should be exercised when co-administering with other immunosuppressants or biologics. Always inform your doctor about all medications, supplements, and herbal products you are taking.
Ebglyss is administered as a subcutaneous injection. The initial dose is typically higher (loading dose) to achieve therapeutic levels quickly, followed by maintenance doses every two or four weeks. Your doctor will determine the appropriate dosing regimen based on your condition and response to treatment.
Clinical trials have evaluated the long-term safety and efficacy of Ebglyss. While generally considered safe for long-term use in appropriate patients, ongoing monitoring for side effects, particularly infections and eye conditions, is important. Your doctor will regularly assess your need for continued treatment.
The duration of side effects can vary. Common side effects like injection site reactions often resolve within a few hours to days. Other effects, such as eye irritation or headaches, may persist for longer but often improve with symptomatic treatment. If any side effect is persistent or worsens, consult your doctor.
Weight gain has not been identified as a common or direct side effect of Ebglyss in clinical trials. If you experience unexpected weight changes, discuss them with your doctor, as they may be related to other factors or conditions.
If you miss a dose of Ebglyss, contact your healthcare provider for guidance. They will advise you on when to take your next dose to maintain effective treatment.
Ebglyss is a targeted immunomodulator. While it affects specific parts of the immune system (by blocking IL-13), it is not a broad immunosuppressant in the same way as some other medications. However, by altering immune responses, it can increase the risk of certain infections, hence the importance of monitoring.
Ebglyss (Lebrikizumab) represents a valuable treatment option for individuals living with moderate-to-severe atopic dermatitis, offering significant improvements in skin health and quality of life. Understanding its side effect profile is an integral part of safe and effective treatment. While most side effects are mild and manageable, awareness of potential serious reactions and prompt communication with your healthcare provider are paramount. By working closely with your doctor, you can navigate your treatment journey with Ebglyss, ensuring the best possible outcomes for your atopic dermatitis management.
Curious if Pepto-Bismol can help your stomach after drinking? We explore the potential risks and what the research says about mixing Pepto-Bismol and alcohol, plus safer alternatives for hangover relief.
April 1, 2026